New standards of care for treatment of diffuse large B-cell lymphoma

Br J Haematol. 2024 Apr;204(4):1132-1134. doi: 10.1111/bjh.19295. Epub 2024 Jan 22.

Abstract

Treatment of newly diagnosed diffuse large B-cell lymphoma with rituximab and CHOP (R-CHOP) has been largely unchanged for the last two decades. The Guideline by Fox et al. provides new evidence-based therapeutic strategies informed by positive results of randomised clinical trials. Commentary on: Fox et al. The management of newly diagnosed large B-cell lymphoma: A British Society for Haematology Guideline. Br J Haematol 2024; 204:1178-1192.

Keywords: DLBCL; chemotherapy; immunotherapy; lymphomas.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Humans
  • Lymphoma, Large B-Cell, Diffuse* / diagnosis
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Prednisone / therapeutic use
  • Randomized Controlled Trials as Topic
  • Rituximab / therapeutic use
  • Standard of Care*
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • Cyclophosphamide
  • Doxorubicin
  • Prednisone
  • Rituximab
  • Vincristine
  • R-CHOP protocol